RecruitingNCT07002034
RE104 for depressive symptoms in adjustment disorder
About this title
Read the official source — NCT07002034Medication studyAges 18–80United States
Understand this study
Who could participate?
Listed age limits: 18 years to 80 years.
What will I do during this study?
The registry summary describes a placebo (an inactive comparison treatment)-controlled comparison of single subcutaneous RE104 injections at 1.5 mg or 30 mg. The reviewed arm fields list the two RE104 dose groups; they do not give a full visit schedule.
- Listed locations
- Birmingham and 31 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Participation duration
- The listed RE104 treatment is a single injection.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: July 30, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 100
- Sponsor
- Reunion Neuroscience Inc
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 80 Years
- Official registry ID
- NCT07002034
- Official title
Show the full official title
A Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Adjustment Disorder in Patients With Cancer and Other Medical Illnesses
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Birmingham · Tucson · San Diego
28 more locations
- Santa Rosa
- Aurora
- Tampa
- Atlanta
- Honolulu
- Chicago
- Kansas City
- Shreveport
- Rockville
- Towson
- Boston
- Worcester
- Ann Arbor
- Novi
- Omaha
- Albuquerque
- Buffalo
- New York
- Chapel Hill
- Cleveland
- Columbus
- Philadelphia
- Knoxville
- Austin
- Draper
- Charlottesville
- Seattle
- Madison
Registry details
Registry conditions (original wording)
Adjustment Disorder
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Reunion Neuroscience Inc.
Does this study involve medication?
Yes. The study involves medication, including RE104 for Injection.
Who can participate?
Listed age limits: 18 years to 80 years.
Is this study still recruiting?
The registry lists this study as recruiting.
